Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SVR005
MIFTS: 46

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Pre-Eclampsia

About this section

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 11 53 14 71 31 33
Severe Preeclampsia 11 14
Severe Pre-Eclampsia, Antepartum Condition or Complication 71
Severe Pre-Eclampsia, Postpartum Condition or Complication 71
Severe Pet - [pre-Eclamptic Toxaemia] 33
Severe Pre-Eclampsia, with Delivery 11
Antepartum Severe Pre-Eclampsia 11
Postpartum Severe Pre-Eclampsia 11
Severe Puerperal Pre-Eclampsia 33
Severe Pre-Eclamptic Toxaemia 33
Severe Toxemia 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Reproductive diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:13129
ICD9CM 34 642.50
ICD10 31 O14.1
ICD11 33 479404771
UMLS 71 C0156669 C0156672 C0156673 more
Sources

Summaries for Severe Pre-Eclampsia

About this section

Disease Ontology: 11 A pre-eclampsia that has symptom at least one of the following: SBP of 160mm HG or higher or DPB of 110mm HG or higher on 2 occasions at least 6 hours apart, proteinuria more than 5g in a 24-hour collection, pulmonary edema or cyanosis, oliguria, persistent headaches, epigastric pain and/or impaired liver function, thrombocytopenia, oligohydramnios, decreased fetal growth or placental abruption.

MalaCards based summary: Severe Pre-Eclampsia, also known as severe preeclampsia, is related to hellp syndrome and eclampsia, and has symptoms including at least one of the following An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Methyldopa and Magnesium sulfate have been mentioned in the context of this disorder. Affiliated tissues include liver, placenta and lung, and related phenotypes are homeostasis/metabolism and cardiovascular system
Sources

Related Diseases for Severe Pre-Eclampsia

About this section

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 357)
# Related Disease Score Top Affiliating Genes
1 hellp syndrome 31.5 SERPINE1 SERPINC1 PGF LGALS13 LEP FLT1
2 eclampsia 31.4 SERPINC1 PGF PAPPA OXT LGALS13 HLA-G
3 disseminated intravascular coagulation 30.8 SERPINE1 SERPINC1 F5 ADAMTS13
4 thrombocytopenia 30.8 SERPINE1 SERPINC1 F5 ENG APOH ADAMTS13
5 thrombophilia due to thrombin defect 30.8 SERPINE1 SERPINC1 F5 APOH
6 gestational trophoblastic neoplasm 30.8 PGF PAPPA OXT MIR517A
7 oligohydramnios 30.6 PGF PAPPA OXT MIR517A
8 pre-eclampsia 30.6 VCAM1 SERPINE1 SERPINC1 PGF PAPPA OXT
9 purpura 30.6 SERPINC1 APOH ADAMTS13
10 hypertensive encephalopathy 30.5 PGF FLT1 ADAMTS13
11 thrombophilia 30.5 SERPINE1 SERPINC1 F5 APOH
12 pregnancy loss, recurrent 1 30.4 HLA-G F5 APOH
13 thrombophilia due to activated protein c resistance 30.4 SERPINE1 SERPINC1 F5 APOH
14 antithrombin iii deficiency 30.4 SERPINC1 F5 APOH
15 intracranial hypertension 30.4 SERPINC1 F5 APOH
16 hemolytic-uremic syndrome 30.4 SERPINE1 SERPINC1 CFHR2 ADAMTS13
17 hepatic infarction 30.3 SERPINC1 CFHR2 APOH
18 ovarian hyperstimulation syndrome 30.3 SERPINC1 FLT1 F5
19 hyperhomocysteinemia 30.3 VCAM1 SERPINE1 SERPINC1 F5 APOH
20 abdominal obesity-metabolic syndrome 1 30.3 SERPINE1 LEP IGFBP1 ADIPOQ
21 pulmonary embolism 30.3 SERPINE1 SERPINC1 F5 APOH
22 von willebrand's disease 30.3 SERPINC1 F5 ADAMTS13
23 thrombotic thrombocytopenic purpura 30.3 SERPINE1 SERPINC1 CFHR2 APOH ADAMTS13
24 fatty liver disease 30.3 VCAM1 SERPINE1 LEP ADIPOQ
25 amenorrhea 30.2 OXT LEP ADIPOQ
26 amaurosis fugax 30.2 SERPINE1 F5
27 nonbacterial thrombotic endocarditis 30.2 SERPINC1 APOH
28 placental abruption 30.2 SERPINC1 PGF PAPPA OXT MIR517A FLT1
29 liver cirrhosis 30.1 SERPINC1 LEP ADIPOQ ADAMTS13
30 persistent fetal circulation syndrome 30.1 PGF OXT MIR517A LEP HLA-G
31 chronic kidney disease 30.1 LEP IGFBP1 CFHR2 ADIPOQ ADAMTS13
32 budd-chiari syndrome 30.1 SERPINC1 F5 APOH
33 glucose intolerance 30.1 VCAM1 LEP IGFBP1 ADIPOQ
34 endocarditis 30.1 VCAM1 SERPINE1 SERPINC1 APOH
35 protein s deficiency 30.1 SERPINE1 SERPINC1 F5 APOH
36 placental insufficiency 30.1 SERPINE1 SERPINC1 PGF PAPPA MIR520A LEP
37 kidney disease 30.0 VCAM1 SERPINE1 PAPPA LEP IGFBP1 ENG
38 stroke, ischemic 30.0 SERPINE1 SERPINC1 F5 ENG APOH ADAMTS13
39 lipid metabolism disorder 30.0 VCAM1 SERPINE1 LEP ADIPOQ
40 gestational diabetes 30.0 PGF PAPPA LEP IGFBP1 FLT1 ADIPOQ
41 polycystic ovary syndrome 30.0 SERPINE1 LEP IGFBP1 ADIPOQ
42 exudative vitreoretinopathy 1 30.0 PGF IGFBP1 FLT1
43 thrombosis 30.0 VCAM1 SERPINE1 SERPINC1 F5 APOH ADAMTS13
44 twin-to-twin transfusion syndrome 29.9 PGF PAPPA FLT1 ENG
45 ectopic pregnancy 29.9 PAPPA OXT MIR517A HLA-G
46 placenta praevia 29.9 PGF PAPPA OXT MIR517A
47 preterm premature rupture of the membranes 29.9 PGF PAPPA OXT IGFBP1
48 antiphospholipid syndrome 29.9 VCAM1 SERPINE1 SERPINC1 PGF F5 APOH
49 mild pre-eclampsia 29.9 VCAM1 SERPINC1 PGF PAPPA OXT MIR517A
50 blood platelet disease 29.9 SERPINC1 CFHR2 APOH ADAMTS13

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia
Sources

Symptoms & Phenotypes for Severe Pre-Eclampsia

About this section

Symptoms:

11
  • • at least one of the following

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 ADAMTS13 ADIPOQ APOH ENG F5 FLT1
2 cardiovascular system MP:0005385 9.4 ADIPOQ ENG F5 FLT1 HLA-G LEP
Sources

Drugs & Therapeutics for Severe Pre-Eclampsia

About this section

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 4138 38853
2
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
3
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5 Sympatholytics Phase 4
6 Hormones Phase 4
7 Calcium, Dietary Phase 4
8 calcium channel blockers Phase 4
9 Tocolytic Agents Phase 4
10 Anti-Arrhythmia Agents Phase 4
11 Anticonvulsants Phase 4
12 Analgesics Phase 4
13 Pharmaceutical Solutions Phase 4
14 Sodium Potassium Chloride Symporter Inhibitors Phase 4
15 diuretics Phase 4
16 Sodium Channel Blockers Phase 4
17 Anesthetics, Local Phase 4
18 Diuretics, Potassium Sparing Phase 4
19
Calcium Nutraceutical Phase 4 7440-70-2 271
20
Carbetocin Approved, Investigational Phase 3 37025-55-1 16681432
21
Misoprostol Approved Phase 3 59122-46-2 5282381
22
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
23
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
24
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
25
Acetylsalicylic acid Approved, Vet_approved Phase 3 50-78-2 2244
26
Reviparin Approved, Investigational Phase 3 9041-08-1
27
Digoxin Approved Phase 2, Phase 3 20830-75-5 3062 2724385 30322
28
Nicardipine Approved, Investigational Phase 3 55985-32-5 4474
29
Urapidil Investigational Phase 3 34661-75-1
30 Anti-Ulcer Agents Phase 3
31 Antacids Phase 3
32 Gastrointestinal Agents Phase 3
33 Analgesics, Non-Narcotic Phase 2, Phase 3
34 Antirheumatic Agents Phase 2, Phase 3
35 Antipyretics Phase 2, Phase 3
36 Cyclooxygenase Inhibitors Phase 2, Phase 3
37 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
38 Anti-Inflammatory Agents Phase 2, Phase 3
39 Fibrinolytic Agents Phase 3
40 Acetylsalicylic acid lysinate Phase 3
41 Platelet Aggregation Inhibitors Phase 3
42 Calcium heparin Phase 3
43 Heparin, Low-Molecular-Weight Phase 3
44 Antihypertensive Agents Phase 3
45 Adrenergic Antagonists Phase 3
46 Adrenergic alpha-Antagonists Phase 3
47 Adrenergic alpha-1 Receptor Antagonists Phase 3
48 Vasodilator Agents Phase 3
49 Cardiotonic Agents Phase 2, Phase 3
50 Protective Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Unknown status NCT03318211 Phase 4 Magnesium Sulfate
3 Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial. Completed NCT03164304 Phase 4 Magnesium Sulfate
4 Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
5 A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
6 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
7 Lignocaine Nebulization for Attenuation of Intubation Stress Response in Patients With Severe Pre-eclampsia: a Prospective Double-blinded Placebo-controlled Trial Recruiting NCT04441073 Phase 4 Lignocaine;Placebo
8 Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
9 Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy Unknown status NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
10 Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
11 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
12 A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
13 Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery. Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
14 The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial Completed NCT01846156 Phase 3 MgSO4
15 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial . Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
16 Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
17 A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia Recruiting NCT04182373 Phase 3 Antithrombin gamma;physiological saline
18 A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia Terminated NCT03008616 Phase 2, Phase 3
19 The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial Terminated NCT02558023 Phase 3 Urapidil;Nicardipine
20 Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
21 Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
22 Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
23 A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
24 Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study Suspended NCT04725812 Phase 2 Eculizumab
25 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
26 Ä°s There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? Unknown status NCT01906567
27 Serum Androgen Levels as a Marker for the Severity of Preeclampsia Unknown status NCT03744988
28 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
29 The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia Unknown status NCT03891498 MgSO4
30 Prognostic Value of Human Epididymis Protein 4 (HE4) for Persistent Proteinuria in Women With Severe Preeclampsia / HELLP Syndrome Unknown status NCT03891394
31 Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study) Unknown status NCT02633995
32 Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia, a Randomized Study Unknown status NCT02373839
33 Detection of Epileptiform Activity in Severe Preeclampsia: A Prospective Observational Pilot Study Unknown status NCT03494517 Magnesium Sulfate
34 Impedance Cardiographic Assessment of Gravidas With Severe Hypertension (ICASH)to Assess Impact of Standard Therapy on Hemodynamic Parameters - A Pilot Study Completed NCT01248169
35 Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia Completed NCT05310929 Labetalol and Glyceril trinitrate
36 Serum Magnesium Level Between Administered Rate of 2 g/hr Versus 2.5 g/hr in Severe Pre-eclampsia Obese Pregnancy, Multicentered Randomized Study Completed NCT03661775 Magnesium sulfate administration
37 Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach Completed NCT02164370
38 Pré-Eclampsie et Retard de Croissance: Une étude Longitudinale Évaluative (PERLE) Completed NCT02379832
39 Statistical Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Severe Preeclampsia in a Low-resource Setting, Mpilo Central Hospital, Bulawayo, Zimbabwe. Completed NCT04058405
40 First-trimester Prediction of Preeclampsia and Other Placenta-mediated Pregnancy Complications Completed NCT02189148
41 Association Between Restless Leg Syndrome and Severe Preeclampsia. A Case Control Study. Completed NCT01538147
42 Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients With Severe Preeclampsia: A Randomized Controlled Trial Completed NCT04222855 Diltiazem
43 PREDICTION OF FLUID RESPONSIVENESS WITH PASSIVE LEG RISING IN PREGNANT PATIENTS WITH SEVERE PREECLAMPSIA Completed NCT03755843
44 Carbetocin Versus Combined Oxytocin and Misoprostol for Prevention of Postpartum Hemorrhage in Women With Severe Preeclampsia Completed NCT04756661 Carbetocin;Oxytocin;Misoprostol
45 Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia Completed NCT00719654
46 The Maternal and Neonatal Impact of Early Versus Delayed Umbilical Cord Clamping Among Pregnant Severe Preeclampsia Patients Delivered by Cesarean Section Completed NCT04193345
47 Increased Salt Sensitivity of Ambulatory Blood Pressure in Women With a History of Severe Preeclampsia Completed NCT01874990
48 Optic Nerve Sheath Diameter Versus Extra-vascular Lung Water Detected by Ultrasound in Volume Status Prediction in Severe Preeclampsia Completed NCT04367519
49 Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia Completed NCT00004399 magnesium sulfate;nimodipine
50 Risk Analysis of Intensive Care Management on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia Completed NCT03412552 MgSO4

Search NIH Clinical Center for Severe Pre-Eclampsia

Sources

Genetic Tests for Severe Pre-Eclampsia

About this section
Sources

Anatomical Context for Severe Pre-Eclampsia

About this section

Organs/tissues related to Severe Pre-Eclampsia:

MalaCards : Liver, Placenta, Lung, Endothelial, Kidney, Neutrophil, Heart
Sources

Publications for Severe Pre-Eclampsia

About this section

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 4115)
# Title Authors PMID Year
1
The 3'-untranslated region of the HLA-G gene in relation to pre-eclampsia: revisited. 53 62
20070604 2010
2
Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy. 53 62
19811467 2009
3
Is there any link between severe pre-eclampsia and defined polymorphisms in leptin and adiponectin genes? 53 62
18958929 2008
4
Antithrombin improves fetal condition in women with severe pre-eclampsia before 32 weeks of gestation; a randomized, double-blind, placebo-controlled trial. 53 62
18226126 2008
5
Effect of sera on the adhesion of natural killer cells to the endothelium in severe pre-eclampsia. 53 62
16984509 2006
6
[Expression of Fas antigen and ligand, placental growth factor in placenta of pregnant women with pre-eclampsia]. 53 62
15938782 2005
7
Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. 53 62
16147638 2004
8
Recent progress in the therapeutic management of pre-eclampsia. 53 62
15500369 2004
9
Serum leptin levels and uterine Doppler flow velocimetry at 20 weeks' gestation as markers for the development of pre-eclampsia. 53 62
15697078 2004
10
Serum levels of leptin, insulin-like growth factor-I and insulin-like growth factor binding protein-3 in women with pre-eclampsia, and their relationship to insulin resistance. 53 62
15497497 2004
11
Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia. 53 62
15001368 2004
12
Antinuclear antibody testing in obstetric patients. 53 62
14750494 2003
13
Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. 53 62
12572596 2002
14
Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? 53 62
11888101 2002
15
The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies. 53 62
11133008 2000
16
Transport and metabolism of serotonin in the human placenta from normal and severely pre-eclamptic pregnancies. 53 62
10729753 2000
17
Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. 53 62
10611266 2000
18
Studies on the HLA-DRB1 genotypes in Japanese women with severe pre-eclampsia positive and negative for anticardiolipin antibody using a polymerase chain reaction-restriction fragment length polymorphism method. 53 62
10601082 1999
19
Vascular cell adhesion molecule-1 (VCAM-1) and leukocyte activation in pre-eclampsia and eclampsia. 53 62
9856316 1998
20
Detection of factor V Leiden mutation in severe pre-eclamptic Hungarian women. 53 62
9712539 1998
21
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. 53 62
8863672 1996
22
Insulin-like growth factors and their binding proteins in normal and abnormal human fetal growth. 53 62
7532055 1994
23
Lupus anticoagulant in pre-eclampsia and intra-uterine growth retardation. 53 62
1773868 1991
24
Reduced left ventricular function and sustained hypertension in women seven years after severe preeclampsia. 62
35852091 2022
25
Left ventricular function and N-terminal pro b-type natriuretic peptide levels in women with hypertensive disorders of pregnancy: A prospective observational study. 62
35304737 2022
26
The influence of hypertensive disorders during pregnancy on the perinatal outcome of different chorionic twins. 62
34180344 2022
27
Means of reaching successful antenatal transfers to level 3 hospitals in cases of threatened very preterm deliveries: a national survey. 62
33980114 2022
28
Expression and significance of let-7a and tumor necrosis factor-alpha in placenta of severe preeclampsia. 62
34284684 2022
29
Usefulness of USCOM® evaluation in women with chronic hypertension who developed severe preeclampsia with low platelets and elevated liver enzymes. 62
33455505 2022
30
Delivery timing in dichorionic diamniotic twin pregnancies complicated by preeclampsia: a decision analysis. 62
35437110 2022
31
Placental oxidative stress and monoamine oxidase expression are increased in severe preeclampsia: a pilot study. 62
35695948 2022
32
HIF1 inhibitor acriflavine rescues early-onset preeclampsia phenotype in mice lacking placental prolyl hydroxylase domain protein 2. 62
36227697 2022
33
Calculated blood loss at cesarean delivery in patients with preeclampsia with severe features on magnesium sulfate. 62
34470131 2022
34
Baseline renal function and adverse outcomes in pregnancies complicated by pregestational diabetes. 62
36411676 2022
35
Edema associated with low plasma protein level and any gestational hypertension as warning signs of HELLP syndrome. 62
34256662 2022
36
Association of Endometriosis and Severe Maternal Morbidity. 62
36357981 2022
37
Critical Hypermagnesemia in Preeclamptic Women Under a Magnesium Sulfate Regimen: Incidence and Associated Risk Factors. 62
36413336 2022
38
Epidemiological characteristics and risk factors of obstetric infection after the Universal Two-Child Policy in North China: a 5-year retrospective study based on 268,311 cases. 62
36418982 2022
39
Skipping breakfast during pregnancy and hypertensive disorders of pregnancy in Japanese women: the Tohoku medical megabank project birth and three-generation cohort study. 62
36397086 2022
40
A Retrospective Case-Control Study on the Diagnostic Values of Hemostatic Markers in Hypertensive Disorder of Pregnancy. 62
36355580 2022
41
Decreased junctional adhesion molecule 3 expression induces reactive oxygen species production and apoptosis in trophoblasts†. 62
35871541 2022
42
Is gestational age at term a risk factor for ongoing pregnancies in nulliparous women: a prospective cohort study. 62
36371036 2022
43
Maternal and infant hospitalization costs associated with hypertensive disorders of pregnancy in a California cohort. 62
33722149 2022
44
The Imbalance of Circulating Monocyte Subgroups with a Higher Proportion of the CD14+CD16+CD163+ Phenotype in Patients with Preeclampsia. 62
36460232 2022
45
The protective effect of magnesium sulfate on placental inflammation via suppressing the NF-κB pathway in a preeclampsia-like rat model. 62
36435037 2022
46
Resolution of preeclampsia after selective termination in discordant twins: A case report and literature review. 62
36451417 2022
47
The Unforeseen Impact of the COVID-19 Pandemic on Dismal Pregnancy and Fetal Outcomes. 62
36475174 2022
48
Admission into intensive care unit in preeclampsia: a four-year population-based study in Reunion Island. 62
33207978 2022
49
Atypical presentation of severe pre-eclampsia with sinus bradycardia and chest pain. 62
36345902 2022
50
A One-Year Cross Sectional Analysis of Emergency Medical Services Utilization and Its Association with Hypertension in Pregnancy. 62
34605746 2022
Sources

Variations for Severe Pre-Eclampsia

About this section
Sources

Expression for Severe Pre-Eclampsia

About this section
Search GEO for disease gene expression data for Severe Pre-Eclampsia.
Sources

Pathways for Severe Pre-Eclampsia

About this section

Pathways related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
Show member pathways
 11.93 SERPINC1 PAPPA IGFBP1 F5
2
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.23 VCAM1 LEP ENG ADIPOQ
3
Nonalcoholic fatty liver disease 74
10.99 VCAM1 LEP ADIPOQ
4
HIF-1-alpha transcription factor network 61
10.74 SERPINE1 LEP IGFBP1 ENG
5
Glypican 1 network 61
10.65 SERPINC1 FLT1
6
VEGF ligand-receptor interactions 66
Show member pathways
 10.53 PGF FLT1
Sources

GO Terms for Severe Pre-Eclampsia

About this section

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.05 ADAMTS13 ADIPOQ APOH CFHR2 F5 FLT1
2 extracellular space GO:0005615 9.83 ADAMTS13 ADIPOQ APOH CFHR2 ENG F5

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 10.01 SERPINE1 PGF FLT1 ENG
2 positive regulation of interleukin-8 production GO:0032757 9.93 SERPINE1 LEP ADIPOQ
3 angiogenesis GO:0001525 9.86 SERPINE1 PGF LEP FLT1 ENG
4 response to activity GO:0014823 9.85 OXT LEP ADIPOQ
5 response to nutrient GO:0007584 9.83 VCAM1 LEP ADIPOQ
6 response to sucrose GO:0009744 9.62 ADIPOQ OXT
7 female pregnancy GO:0007565 9.56 PGF PAPPA OXT LEP
8 hemostasis GO:0007599 9.33 SERPINC1 F5 ADAMTS13
9 response to hypoxia GO:0001666 9.28 VCAM1 PGF LEP ENG ADIPOQ
Sources

Sources for Severe Pre-Eclampsia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....